Barclays PLC Acquires 42,012 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN)

Barclays PLC lifted its holdings in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) by 295.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 56,217 shares of the company’s stock after purchasing an additional 42,012 shares during the quarter. Barclays PLC owned 0.12% of Enliven Therapeutics worth $1,435,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of ELVN. Quest Partners LLC grew its stake in Enliven Therapeutics by 87.3% in the 2nd quarter. Quest Partners LLC now owns 1,592 shares of the company’s stock worth $37,000 after buying an additional 742 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its position in Enliven Therapeutics by 64.4% in the third quarter. China Universal Asset Management Co. Ltd. now owns 9,085 shares of the company’s stock worth $232,000 after acquiring an additional 3,559 shares in the last quarter. SG Americas Securities LLC bought a new position in Enliven Therapeutics in the third quarter valued at $256,000. Verition Fund Management LLC purchased a new stake in Enliven Therapeutics during the third quarter valued at about $271,000. Finally, The Manufacturers Life Insurance Company bought a new stake in Enliven Therapeutics during the second quarter worth about $322,000. 95.08% of the stock is currently owned by institutional investors.

Enliven Therapeutics Price Performance

Shares of Enliven Therapeutics stock opened at $21.74 on Monday. Enliven Therapeutics, Inc. has a one year low of $10.90 and a one year high of $30.03. The business’s 50 day simple moving average is $24.54 and its two-hundred day simple moving average is $24.43. The stock has a market capitalization of $1.06 billion, a P/E ratio of -11.44 and a beta of 1.04.

Wall Street Analyst Weigh In

Several brokerages have recently commented on ELVN. Robert W. Baird increased their price objective on Enliven Therapeutics from $32.00 to $40.00 and gave the company an “outperform” rating in a research report on Friday, November 15th. BTIG Research assumed coverage on shares of Enliven Therapeutics in a research note on Friday, December 13th. They set a “buy” rating and a $42.00 price target on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and set a $37.00 target price on shares of Enliven Therapeutics in a report on Tuesday, October 1st. Four investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $38.25.

Insider Transactions at Enliven Therapeutics

In related news, CFO Benjamin Hohl sold 3,350 shares of the business’s stock in a transaction dated Friday, December 27th. The stock was sold at an average price of $22.15, for a total transaction of $74,202.50. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, COO Anish Patel sold 21,700 shares of the company’s stock in a transaction that occurred on Tuesday, January 7th. The shares were sold at an average price of $24.18, for a total value of $524,706.00. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 43,838 shares of company stock worth $1,112,061. Insiders own 29.20% of the company’s stock.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.